A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

Recruiting

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(9 sites)

South Korea

Pusan National University Yangsan Hospital, Busan

Kyungpook National University Hospital, Daegu

Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

Gangnam Severance Hospital, Seoul

Kangbuk Samsung Medical Center, Seoul